WO2024141995 - COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES

National phase entry:
Publication Number WO/2024/141995
Publication Date 04.07.2024
International Application No. PCT/IB2023/063354
International Filing Date 28.12.2023
Title **
[English] COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES
[French] COMPOSITIONS, SYSTÈMES ET MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE DE CHAMPS DE TRAITEMENT DE TUMEUR ET D'ANTICORPS ANTI-VEGFR-2
Applicants **
NOVOCURE GMBH
Inventors
VOLOSHIN-SELA, Tali
KLEIN-GOLDBERG, Anat
AVIGDOR, Lilach
Priority Data
63/477,396   28.12.2022   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2078
EPO Filing, Examination, Granting8421
Japan Filing, Examination, Granting2176
South Korea Filing, Examination, Granting2051
USA Filing, Examination, Granting5340
MasterCard Visa
Total: 20,066

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising at least one antibody that specifically binds to a vascular endothelial growth factor receptor-2 (anti-VEGFR-2 antibody).[French] Des compositions, des systèmes et des méthodes pour réduire la viabilité de cellules cancéreuses et traiter le cancer, ainsi que pour prévenir une augmentation du volume d'une tumeur présente dans le corps d'un patient vivant sont divulgués. Les systèmes et les procédés impliquent l'application d'un champ alternatif en association avec l'administration d'au moins une composition comprenant au moins un anticorps qui se lie spécifiquement à un récepteur 2 du facteur de croissance endothéliale vasculaire (anticorps anti-VEGFR-2).

Rejoining the server...